Spruce Biosciences, Inc.
SPRB
$60.95
$0.891.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -135.84% | 1,265.35% | |||
| Gross Profit | 135.84% | -1,265.35% | |||
| SG&A Expenses | 55.25% | 3.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -61.11% | 205.68% | |||
| Operating Income | 61.11% | -205.68% | |||
| Income Before Tax | -78.35% | -297.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -78.35% | -297.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -78.35% | -297.29% | |||
| EBIT | 61.11% | -205.68% | |||
| EBITDA | 61.16% | -206.37% | |||
| EPS Basic | 22.62% | -317.09% | |||
| Normalized Basic EPS | 64.36% | -317.10% | |||
| EPS Diluted | 22.62% | -317.09% | |||
| Normalized Diluted EPS | 64.36% | -317.10% | |||
| Average Basic Shares Outstanding | 130.47% | -4.74% | |||
| Average Diluted Shares Outstanding | 130.47% | -4.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||